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formerly known as anti-p155), which has been 
shown to be useful in the diagnosis of cancer-
associated myositis.2,3 In the reported case, 
negativity for this antibody would imply that the 
improvement in dermatomyositis was due to 
the administration of ruxolitinib rather than to 
the improvement in the hematologic cancer. We 
think that such a determination would help in 
better understanding the excellent response to 
this drug.
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The authors reply: Dermatomyositis is known 
to be associated with cancers in approximately 
25% of patients with the condition. However, 
dermatomyositis occurring in the course of myelo-
fibrosis is extremely rare. Anti-TIF1γ antibodies 
have been linked to paraneoplastic dermatomyo-
sitis, but their clinical significance is still contro-
versial, and the antibody level is not routinely 
measured.1
In our patient, we believe that the dramatic 
and rapid clinical effects were due to the anti-
inflammatory properties of the Janus kinase 
(JAK) inhibitor, even though we cannot rule out 
the possibility that myelofibrosis-induced in-
flammation triggering dermatomyositis also 
might have been inhibited. Ruxolitinib induces 
only very limited activity against the JAK2-mutat-
ed clone, and its therapeutic effects in myelofi-
brosis are not determined by the patient’s JAK2 
mutational status, which supports the idea that 
clinical improvement is not due to a reduction in 
the tumor burden.2 Thus, inhibition of the pro-
duction or secretion of cutaneous proinflamma-
tory key cytokines (CXCL9 and CXCL10) appears 
to be the predominant therapeutic effect of the 
drug.3 This idea is further supported by the po-
tent antiinflammatory capacity of ruxolitinib in 
graft-versus-host disease, a disorder in which the 
histologic and immunologic patterns show strik-
ing similarities to those of dermatomyositis.4,5
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Ebola	Virus	Disease	among	Children	in	West	Africa
To the Editor: The epidemic of Ebola virus dis-
ease (EVD) in West Africa has caused clinical ill-
ness and deaths among persons with reported 
ages ranging from less than 1 year to more than 
100 years. Most published estimates of key epide-
miologic parameters have been based on patients 
of all ages1,2 and have thus been dominated by 
cases in which patients are 16 years of age or 
older, and as of January 5, 2015, these cases ac-
counted for 79% of the confirmed and probable 
cases for which age has been reported.
Here we investigate the progression and out-
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come of EVD in confirmed and probable pediatric 
cases reported from Guinea, Liberia, and Sierra 
Leone, stratified according to age. The absolute 
and per capita case incidence of EVD among 
children younger than 16 years of age has been 
significantly and consistently lower than the 
incidence among adults in all three countries 
(Fig. 1A, 1B, and 1C). This pattern is similar to 
that observed in past EVD outbreaks.3,4 However, 
because the current epidemic is so large, it pro-
vides an opportunity to explore the ways in 
which epidemiologic and clinical parameters vary 
according to age. Although the age distribution 
of confirmed, probable, and suspected cases is 
similar in all three countries (Fig. S3 in the 
Supplementary Appendix, available with the full 
text of this letter at NEJM.org), the proportion of 
pediatric cases (those younger than 16 years of 
age) among all cases increased over the course 
of 2014 (Fig. 1C, and Fig. S4 in the Supplemen-
tary Appendix).
The mean incubation period (the average time 
from infection until symptom onset) was short-
est, on average, in the youngest children, with 
means ranging from 6.9 days (95% confidence 
interval [CI], 5.1 to 9.5) in 14 children younger 
than 1 year of age to 9.8 days (95% CI, 8.7 to 
11.1) in 184 children 10 to 15 years of age (Fig. 
1D, and Table S1 and Fig. S5 in the Supplemen-
tary Appendix). Younger children also had short-
er times from symptom onset to hospitalization 
and from symptom onset to death (Fig. 1D, and 
Fig. S6 and S7 and Tables S2 and S3 in the 
Supplementary Appendix). There was no clear 
evidence that age affected the distribution of the 
intervals between symptom onset and hospital 
discharge, between hospitalization and death, 
between hospitalization and hospital discharge, 
or between symptom onset and onward trans-
mission (Fig. S8 to S11 and Tables S4 to S7 in 
the Supplementary Appendix).
Almost all children with EVD who were 
younger than 1 year of age had fever (92%) be-
fore clinical presentation, and children younger 
than 16 years of age were more likely than adults 
to present with fever (P<0.001) (Table S8 and Fig. 
S13 in the Supplementary Appendix). Children 
were less likely than adults (i.e., persons 16 years 
of age or older) to report pain in the abdomen, 
chest, joints, or muscles, difficulty breathing or 
swallowing, and hiccups between symptom on-
set and clinical presentation (P<0.001); however, 
this finding may reflect the difficulty young 
children have in reporting such symptoms rather 
than a different symptom profile (Table S8 and 
Fig. S12 in the Supplementary Appendix). The 
case fatality rate (CFR) was lowest among chil-
dren between 10 and 15 years of age and highest 
among those 4 years of age or younger (Fig. 1E, 
and Fig. S14 and S15 and Table S9 in the Supple-
mentary Appendix). The CFR for persons young-
er than 45 years of age (most of whom are 5 to 
44 years of age) was lower than that among 
those 45 years of age or older (Fig. 1E), a finding 
that is in line with that of an earlier report.5
The shorter incubation period in children, the 
relatively high risk of death among children 
younger than 5 years of age (as compared with 
older children), and the more rapid progression 
to death highlight the importance of including 
children among case contacts for follow-up, of 
examining children for early signs of disease 
during active case finding, and of explaining the 
risk of EVD to parents, guardians, and caregiv-
ers. All persons in whom EVD is suspected, but 
especially children, need the earliest possible 
referral for diagnostic testing, and children need 
age-appropriate treatment. The causes of the 
Figure	1	(next	page).	Age-Group–Specific	Incidence	of	Ebola	Virus	Disease	in	West	Africa,	Incubation	Period,	Inter-
vals	from	Onset	to	Death	and	Onset	to	Hospitalization,	and	Case	Fatality	Rate.
Panel A shows the cumulative incidence of confirmed and probable cases of Ebola virus disease (EVD) according to 
age group and country. Panel B shows the cumulative incidence of confirmed and probable cases per 10,000 popula-
tion according to age group and country. Panel C shows the overall age distribution for confirmed and probable cases 
according to month of symptom onset. Panel D shows the estimated average incubation period, the interval be-
tween symptom onset and death, and the interval between symptom onset and hospitalization according to age 
among persons with confirmed or probable EVD (with vertical lines indicating 95% confidence intervals [CIs]). The 
numbers represent the sample sizes in each age group. Panel E shows the estimated case fatality rate according to age 
among persons with confirmed or probable EVD (with 95% CIs), with representation of the total number of con-
firmed or probable cases of EVD cases in each age group and the total number of confirmed or probable cases of 
EVD for which there was information on the final outcome in each age group. 
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notices
relatively rapid disease progression and relatively 
high CFR in the youngest children requires fur-
ther investigation.
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